Welcome to our dedicated page for Sangamo Therapeutics news (Ticker: $SGMO), a resource for investors and traders seeking the latest updates and insights on Sangamo Therapeutics stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Sangamo Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Sangamo Therapeutics's position in the market.
In the PR, Sangamo Therapeutics reported recent business highlights, including raising $24 million in gross proceeds, progress in neurology pipeline, completion of dosing in Phase 1/2 STAAR study for Fabry disease, and ongoing discussions with potential Fabry collaboration partners. Pfizer anticipates BLA and MAA submissions for Hemophilia A collaboration in early 2025. Financially, Sangamo reported a net loss of $49.1 million in Q1 2024 compared to a net income of $21.1 million in Q1 2023, with revenues decreasing to $0.5 million from $158.0 million in the same period in 2023. The non-GAAP total operating expenses decreased to $43.6 million in Q1 2024 from $69.5 million in Q1 2023. Cash and cash equivalents were $54.4 million as of March 31, 2024.
Sangamo Therapeutics, Inc. presented pre-clinical data on their innovative Modular Integrase (MINT) technology, aimed at large-scale genome editing. The MINT platform utilizes Bxb1 to integrate large DNA sequences into the genome with potential applications in treating patients with unique mutations. The technology is designed to simplify manufacturing, reduce translocation risk, and enable targeted integration without the need for additional genome editing tools. The company views the MINT platform as a valuable tool for neurology-focused indications and potential collaborations in human disease and agricultural biotech.
Sangamo Therapeutics, Inc. (Nasdaq: SGMO) has announced the release of its first quarter 2024 financial results on Thursday, May 9, 2024. The company will hold a conference call at 4:30 p.m. Eastern on the same day to discuss financial results and provide business updates.